Adropin Improves Radiation-Induced Myocardial Injury Via VEGFR2/PI3K/Akt Pathway

Overview

Journal Oxid Med Cell Longev

Publisher Wiley

Specialties Cell Biology
Endocrinology

Date 2022 Aug 4

PMID 35923860

Authors

Bingda Li

Zhenhua Wang

Yuanqiao He

Tianpeng Chen

Yun Zhang

Xingxing Yuan

Ping Li

Affiliations

Soon will be listed here.

Abstract

Mediastinal cancer radiotherapy exposes the heart and causes myocardial injury. It is of utmost importance to identify effective prevention and treatment targets. In this study, the regulatory role of adropin (Ad) in radiation-induced myocardial injury (RIMI) was explored in mice. After C57BL/6 mice were administered E0771 cells and received radiotherapy, the effects of exogenous Ad intervention on myocardial fibrosis, apoptosis, microvessel density, oxidative stress, and protein expression levels were observed. The results showed that exogenous Ad effectively improved cardiac function, suppressed oxidative stress, inhibited myocardial fibrosis, reduced myocardial apoptosis, and promoted microangiogenesis in RIMI mice. Ad also downregulated the expression levels of transforming growth factor 1 (TGF-1), NADPH oxidase 4 (NOX4), and cleaved caspase 3 and upregulated the expression of phosphor-endothelial nitric oxide synthase (p-eNOS). However, the above-mentioned effects of Ad were significantly reversed in Ad mice. Radiotherapy resulted in the downregulation of phosphor-vascular endothelial growth factor receptor (p-VEGFR2) and p-Akt in myocardial tissue, which were upregulated by Ad. However, after targeted inhibition of VEGFR2 with apatinib, the effect of Ad on improving RIMI was significantly reversed. Taken together, exogenous Ad significantly ameliorated RIMI by reducing oxidative stress, promoting microangiogenesis, and inhibiting myocardial fibrosis and apoptosis. The underlying molecular mechanism involved may be elucidated by activation of the VEGFR2/PI3K/Akt pathway.

Citing Articles

Adropin: a key player in immune cell homeostasis and regulation of inflammation in several diseases.

Wang J, Ding N, Chen C, Gu S, Liu J, Wang Y Front Immunol. 2025; 16:1482308.

PMID: 39906123 PMC: 11790448. DOI: 10.3389/fimmu.2025.1482308.

Sex difference in human diseases: mechanistic insights and clinical implications.

Shi Y, Ma J, Li S, Liu C, Liu Y, Chen J Signal Transduct Target Ther. 2024; 9(1):238.

PMID: 39256355 PMC: 11387494. DOI: 10.1038/s41392-024-01929-7.

Unveiling the multifaceted role of adropin in various diseases (Review).

Chen L, Lu J, Hu J, Gong X Int J Mol Med. 2024; 54(4).

PMID: 39155866 PMC: 11335353. DOI: 10.3892/ijmm.2024.5414.

Tissue fibrosis induced by radiotherapy: current understanding of the molecular mechanisms, diagnosis and therapeutic advances.

Yu Z, Xu C, Song B, Zhang S, Chen C, Li C J Transl Med. 2023; 21(1):708.

PMID: 37814303 PMC: 10563272. DOI: 10.1186/s12967-023-04554-0.

Adropin Predicts Chronic Kidney Disease in Type 2 Diabetes Mellitus Patients with Chronic Heart Failure.

Berezina T, Obradovic Z, Boxhammer E, Berezin A, Lichtenauer M, Berezin A J Clin Med. 2023; 12(6).

PMID: 36983232 PMC: 10059962. DOI: 10.3390/jcm12062231.

References

Kostakou P, Kouris N, Kostopoulos V, Damaskos D, Olympios C . Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology. Heart Fail Rev. 2018; 24(1):91-100. DOI: 10.1007/s10741-018-9731-y. View

Kivela R, Hemanthakumar K, Vaparanta K, Robciuc M, Izumiya Y, Kidoya H . Endothelial Cells Regulate Physiological Cardiomyocyte Growth via VEGFR2-Mediated Paracrine Signaling. Circulation. 2019; 139(22):2570-2584. PMC: 6553980. DOI: 10.1161/CIRCULATIONAHA.118.036099. View

Wang Z, Yang B, Chen X, Zhou Q, Li H, Chen S . Nobiletin Regulates ROS/ADMA/DDAHII/eNOS/NO Pathway and Alleviates Vascular Endothelium Injury by Iron Overload. Biol Trace Elem Res. 2020; 198(1):87-97. DOI: 10.1007/s12011-020-02038-6. View

Wang B, Wang H, Zhang M, Ji R, Wei J, Xin Y . Radiation-induced myocardial fibrosis: Mechanisms underlying its pathogenesis and therapeutic strategies. J Cell Mol Med. 2020; 24(14):7717-7729. PMC: 7348163. DOI: 10.1111/jcmm.15479. View

Wang J, Chen Y, Yang Y, Xiao X, Chen S, Zhang C . Endothelial progenitor cells and neural progenitor cells synergistically protect cerebral endothelial cells from Hypoxia/reoxygenation-induced injury via activating the PI3K/Akt pathway. Mol Brain. 2016; 9:12. PMC: 4738765. DOI: 10.1186/s13041-016-0193-7. View

Ushio-Fukai M . VEGF signaling through NADPH oxidase-derived ROS. Antioxid Redox Signal. 2007; 9(6):731-9. DOI: 10.1089/ars.2007.1556. View

Dong H, Zhou Y, Wang Y, Zhou Q, Zhang Y, Gan X . The protective role of intermedin in promoting angiogenesis during renal fibrosis. Gene. 2018; 688:34-43. DOI: 10.1016/j.gene.2018.11.057. View

Lovren F, Pan Y, Quan A, Singh K, Shukla P, Gupta M . Adropin is a novel regulator of endothelial function. Circulation. 2010; 122(11 Suppl):S185-92. DOI: 10.1161/CIRCULATIONAHA.109.931782. View

Slezak J, Kura B, Ravingerova T, Tribulova N, Okruhlicova L, Barancik M . Mechanisms of cardiac radiation injury and potential preventive approaches. Can J Physiol Pharmacol. 2015; 93(9):737-53. DOI: 10.1139/cjpp-2015-0006. View

10.

Lee M, Liu D, Hung S, Yu C, Chi C, Chiou W . Emerging Challenges of Radiation-Associated Cardiovascular Dysfunction (RACVD) in Modern Radiation Oncology: Clinical Practice, Bench Investigation, and Multidisciplinary Care. Front Cardiovasc Med. 2020; 7:16. PMC: 7047711. DOI: 10.3389/fcvm.2020.00016. View

11.

Liu L, Ouyang W, Zhao X, Su S, Yang Y, Ding W . Pathogenesis and Prevention of Radiation-induced Myocardial Fibrosis. Asian Pac J Cancer Prev. 2017; 18(3):583-587. PMC: 5464468. DOI: 10.22034/APJCP.2017.18.3.583. View

12.

Boulet J, Pena J, Hulten E, Neilan T, Dragomir A, Freeman C . Statin Use and Risk of Vascular Events Among Cancer Patients After Radiotherapy to the Thorax, Head, and Neck. J Am Heart Assoc. 2019; 8(13):e005996. PMC: 6662340. DOI: 10.1161/JAHA.117.005996. View

13.

Alzoughool F, Al-Zghoul M . Optimal therapeutic adropin dose intervention in mice and rat animal models: A systematic review. Vet World. 2021; 14(6):1426-1429. PMC: 8304445. DOI: 10.14202/vetworld.2021.1426-1429. View

14.

Mushala B, Scott I . Adropin: a hepatokine modulator of vascular function and cardiac fuel metabolism. Am J Physiol Heart Circ Physiol. 2020; 320(1):H238-H244. PMC: 7847067. DOI: 10.1152/ajpheart.00449.2020. View

15.

Altamimi T, Gao S, Karwi Q, Fukushima A, Rawat S, Wagg C . Adropin regulates cardiac energy metabolism and improves cardiac function and efficiency. Metabolism. 2019; 98:37-48. DOI: 10.1016/j.metabol.2019.06.005. View

16.

Ping Z, Peng Y, Lang H, Xinyong C, Zhiyi Z, Xiaocheng W . Oxidative Stress in Radiation-Induced Cardiotoxicity. Oxid Med Cell Longev. 2020; 2020:3579143. PMC: 7071808. DOI: 10.1155/2020/3579143. View

17.

Sato K, Yamashita T, Shirai R, Shibata K, Okano T, Yamaguchi M . Adropin Contributes to Anti-Atherosclerosis by Suppressing Monocyte-Endothelial Cell Adhesion and Smooth Muscle Cell Proliferation. Int J Mol Sci. 2018; 19(5). PMC: 5983814. DOI: 10.3390/ijms19051293. View

18.

Gao S, McMillan R, Zhu Q, Lopaschuk G, Hulver M, Butler A . Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. Mol Metab. 2015; 4(4):310-24. PMC: 4354928. DOI: 10.1016/j.molmet.2015.01.005. View

19.

Li L, Xie W, Zheng X, Yin W, Tang C . A novel peptide adropin in cardiovascular diseases. Clin Chim Acta. 2015; 453:107-13. DOI: 10.1016/j.cca.2015.12.010. View

20.

Matsumoto T, Claesson-Welsh L . VEGF receptor signal transduction. Sci STKE. 2001; 2001(112):re21. DOI: 10.1126/stke.2001.112.re21. View